Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients

被引:9
|
作者
Macedo, Luciana Conci [1 ]
Quintero, Fernanda de Cesare [2 ]
Pagliari-E-Silva, Sara [3 ]
Barbosa Pagnano, Katia Borgia [4 ]
Rodrigues, Camila [1 ]
de Alencar, Josiane Bazzo [1 ]
Sell, Ana Maria [2 ]
Laguila Visentainer, Jeane Eliete [2 ]
机构
[1] Univ Estadual Maringa, Biomed & Clin Anal Dept, Post Grad Program Biosci & Physiopathol, BR-87020900 Maringa, Parana, Brazil
[2] Univ Estadual Maringa, Basic Hlth Sci Dept, Ave Colombo 5790, BR-87020900 Maringa, Parana, Brazil
[3] Hosp Canc Maringa, Maringa, Parana, Brazil
[4] Univ Estadual Campinas, Ctr Hematol & Hemoterapia Campinas, Sao Paulo, Brazil
关键词
Myeloproliferative disorders; NECROSIS-FACTOR-ALPHA; PROMOTER POLYMORPHISM; GENETIC POLYMORPHISMS; POLYCYTHEMIA-VERA; SUSCEPTIBILITY; LUNG; REGION;
D O I
10.1016/j.bcmd.2015.12.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The classical chromosome Philadelphia-negative myeloproliferative neoplasms (MPNs) are a group of disorders that share clinical, hematological, and histological features. Proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha) are elevated in patients with MPN. The aim of this study was to verify the association between the polymorphisms of TNF gene (-308G/A and-238 G/A) in BCR-ABL-negative MPN in our population. Blood samples obtained from MPN patients were genotyped for the JAK2V617F mutation and both TNF polymorphisms using PCR-RFLP. Thirty three (26.8%) patients with polycythemia vera (PV), 35 (28.7%) essential thrombocythemia (ET), 22 (17.7%) primary myelofibrosis (PMF), and 33 (26.8%) with unclassifiable MPN (MPNu) were included in the study. The JAK2 V617F mutation was detected in 94 (76.42%) patients. Were observed a significant increase on the frequency of the TNF-238 GA genotype in MPN patients compared to controls (OR = 221, 95% Cl = 1.02-4.80, P < 0.04). The distribution of the genotypes and allelic frequencies of TNF-308 was significantly different among the MPNs, JAK2V617F positive, PV and PMF, and controls. Our data has demonstrated that the polymorphisms on TNF-238 GA, TNF-308 GA were associated to MPN development in this population, triggered by JAK2 V617F mutation. (C) 2015 Published by Elsevier Inc.
引用
收藏
页码:54 / 57
页数:4
相关论文
共 50 条
  • [21] Angiogenesis in JAK2 V617F positive myeloproliferative neoplasms and ruxolitinib decrease VEGF, HIF-1 enesis in JAK2 V617F positive cells
    Cheng, Zhiyong
    Fu, Jianzhu
    Liu, Guimin
    Zhang, Lijun
    Xu, Qian
    Wang, Su-yun
    LEUKEMIA & LYMPHOMA, 2018, 59 (01) : 196 - 203
  • [22] No evidence for amplification of V617F JAK2 in myeloproliferative disorders
    Jones, A. V.
    Bunyan, D. J.
    LEUKEMIA, 2007, 21 (12) : 2561 - 2563
  • [23] No evidence for amplification of V617F JAK2 in myeloproliferative disorders
    A V Jones
    D J Bunyan
    N C P Cross
    Leukemia, 2007, 21 : 2561 - 2563
  • [24] JAK2 V617F: implications for thrombosis in myeloproliferative diseases
    Hexner, Elizabeth O.
    CURRENT OPINION IN HEMATOLOGY, 2007, 14 (05) : 450 - 454
  • [25] JAK2 46/1 haplotype is associated with JAK2 V617F-positive myeloproliferative neoplasms in Brazilian patients
    Macedo, L. C.
    Santos, B. C.
    Pagliarini-E-Silva, S.
    Pagnano, K. B. B.
    Rodrigues, C.
    Quintero, F. C.
    Ferreira, M. E.
    Baraldi, E. C.
    Ambrosio-Albuquerque, E. P.
    Sell, A. M.
    Visentainer, J. E. L.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2015, 37 (05) : 654 - 660
  • [26] Presence of JAK2 V617F mutation in myeloproliferative and myelodysplastic syndrome patients
    Duarte, F.
    Santos, T.
    Barbosa, M.
    Santos, T.
    Goncalves, R.
    LEUKEMIA RESEARCH, 2013, 37 : S99 - S100
  • [27] JAK2 V617F mutation and VEGF levels in patients with myeloproliferative disorders
    Bourantas, L.
    Chatzikyriakidou, A.
    Panteli, K.
    Bai, M.
    Bourantas, D. K.
    Tsiara, St.
    Georgiou, I.
    Bourantas, K. L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 547 - 548
  • [28] The clinical value of plasma CFDNA JAK2 V617F mutation detection in myeloproliferative neoplasms
    Wu, Q.
    Cao, G.
    Guan, M.
    CLINICA CHIMICA ACTA, 2024, 558
  • [29] Correlation of JAK2 V617F Mutation Burden with Clinical and Hematologic Characteristics of Myeloproliferative Neoplasms
    Brown, A. F.
    Wang, Y.
    Abu-Ghusson, M. M.
    George, P. A.
    Vadlamudi, K.
    Furmaga, W. B.
    Fan, H.
    MODERN PATHOLOGY, 2013, 26 : 321A - 321A
  • [30] Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms
    Gango, Ambrus
    Mozes, Reka
    Boha, Zsofia
    Kajtar, Bela
    Timar, Botond
    Kiraly, Peter Attila
    Kiss, Richard
    Fesus, Viktoria
    Nagy, Noemi
    Demeter, Judit
    Korosmezey, Gabor
    Borbenyi, Zita
    Marton, Imelda
    Szoke, Anita
    Masszi, Tamas
    Farkas, Peter
    Varkonyi, Judit
    Plander, Mark
    Posfai, Eva
    Egyed, Miklos
    Pal, Katalin
    Radvanyi, Gaspar
    Hamed, Aryan
    Csomor, Judit
    Matolcsy, Andras
    Alpar, Donat
    Bodor, Csaba
    LEUKEMIA RESEARCH, 2018, 65 : 42 - 48